May 22, 2024

Business Active

business the management

Antios Therapeutics Appoints Achieved Money Govt, Tamra J. Adams, as its to start with Main Financial Officer

3 min read

Get within Wall Avenue with StreetInsider Premium. Assert your 1-7 days absolutely free trial right here.


ATLANTA, Feb. 17, 2021 (World NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) nowadays introduced the appointment of seasoned economic govt, Tamra J. Adams, as the Company’s main financial officer (CFO) productive March 1, 2021. Ms. Adams fills a freshly produced govt situation at Antios as component of the Company’s fast development.

“We have a short while ago finished a Stage 1b clinical trial of our lead asset, ATI-2173, a probable backbone cure in a practical curative routine for persistent HBV infection, and anticipate presenting evidence-of-strategy data from the research in mid-2021,” mentioned Gregory Mayes, main executive officer of Antios. “We also glance ahead to aggressively transferring the program into Phase 2 which will commence up coming month. For that reason, adding a senior economic executive expert with emerging growth providers, together with in biopharmaceuticals, to the government management staff is a crucial step at this time. Tamra and I worked carefully with each other at Have interaction Therapeutics for a few several years and I seem forward to collaborating with her again as we continue on to rapidly progress the progress of ATI-2173 and evolve as a business.”

Ms. Adams has far more than 25 yrs of experience in accounting and economic administration. Just before signing up for Antios, she established Accounting Concepts, Inc., a company that provided CFO, accounting, and fiscal services to rising growth firms in the biopharmaceutical and information know-how industries, together with Interact Therapeutics, a enterprise that was sold to UCB in 2020. Ahead of that, Ms. Adams was a senior fiscal executive at Silverstorm Systems, Inc., wherever she was accountable for economic and human assets capabilities and participated in an acquisition of the enterprise by QLogic. Prior, she was the Controller of Starcite, Inc., an world-wide-web business, the place she was dependable for fiscal reporting, business enterprise product advancement and internal command units. Ms. Adams commenced her vocation at Ernst & Younger, LLP, as a Senior Auditor specializing in entrepreneurial solutions and later on at Goldman Sachs as a Senior Accounting Officer. Ms. Adams earned her B.S. in Accounting at Condition University of New York, Albany and is a certified general public accountant in New York.

“I have spent the bulk of my vocation managing the fiscal infrastructure for rising expansion firms and performing with Antios provides me the chance to go on building on that do the job,” said Ms. Adams. “The enterprise is on a speedy growth trajectory and has the likely to make a substantial contribution to community health. I glance ahead to encouraging construct Antios into a leading biopharmaceutical corporation with the rest of the staff.”

About ATI-2173ATI-2173 is a novel, orally administered, liver-targeted Lively Internet site Polymerase Inhibitor Nucleotide (ASPIN) molecule made to provide the 5’-monophosphate of clevudine to the liver. This L-nucleoside’s energetic 5’-triphosphate has distinctive antiviral properties as a non-aggressive, non-chain terminating HBV polymerase inhibitor that distorts the energetic site of HBV polymerase resulting in strong HBV antiviral action and extended off-treatment method suppression of HBV DNA. ATI-2173 targets the liver, providing large concentrations of the unique 5’- triphosphate whilst limiting systemic publicity to the dad or mum L-nucleoside. ATI-2173 has the probable to come to be an integral element of a healing mix routine for serious hepatitis B.

About Antios Therapeutics Inc.Antios Therapeutics is a medical-stage biopharmaceutical company focused on the advancement of revolutionary therapies to deal with and remedy viral conditions. Antios is at present developing ATI-2173, aiming to give persistent hepatitis B contaminated individuals with a curative mixture routine.

CONTACTS

Traders:Lee RothBurns McClellan[email protected] +1 (212) 300-8331

Media: Ryo Imai / Robert Flamm, Ph.D.Burns McClellan[email protected] / [email protected]+1 (212) 300-8315 / +1 (212) 300-8364

Primary Logo

Supply: Antios Therapeutics Inc.

You may have missed